SEO News

Neuroglee gets $2.3 million to develop digital therapeutics for neurodegenerative diseases – TechCrunch

Mr. Aniket Singh Rajput CEO and Founder Neuroglee

There are actually about 50 million people with dementia globally, a quantity the World Well being Group expects to triple by 2050. Alzheimer’s is the main reason behind dementia and caregivers are sometimes overwhelmed, with out sufficient help.

Neuroglee, a Singapore-based well being tech startup, desires to assist with a digital therapeutic platform created to deal with sufferers within the early levels of the illness. Based this 12 months to give attention to neurodegenerative illnesses, Neuroglee introduced at present it has raised $2.three million in pre-seed funding.

The spherical was led by Eisai Co., one in all Japan’s largest pharmaceutical firms, and Kuldeep Singh Rajput, the founder and chief govt officer of predictive healthcare startup Biofourmis.

Neuroglee’s prescription digital remedy software program for Alzheimer’s, referred to as NG-001, is its predominant product. The corporate plans to begin scientific trials subsequent 12 months. NG-001 is supposed to enhance medicine and different therapies, and as soon as it’s prescribed by a clinician, sufferers can entry its cognitive workouts and duties by a pill.

The software program tracks sufferers’ progress, such because the pace of their fingers and the time it takes to finish an train, and delivers personalised remedy applications. It additionally has options to handle the psychological well being of sufferers, together with one which exhibits photos that may deliver up optimistic reminiscences, which in flip will help alleviate despair and anxiousness when utilized in tandem with different cognitive behavioral remedy methods.

For caregivers and clinicians, NG-001 helps them observe affected person progress and their compliance with different therapies, like drugs. Which means that healthcare suppliers can work intently with sufferers even remotely, which is very vital throughout the COVID-19 pandemic.

Neuroglee founder and CEO Aniket Singh Rajput advised PJDM that its first goal markets for NG-001 are the US and Singapore, adopted by Japan. NG-001 wants to achieve regulatory approval in every nation, and it’ll begin by searching for U.S. Meals and Drug Administration clearance.

As soon as it launches, clinicians could have two methods to prescribe NG-001, by their healthcare supplier platform or an digital prescription device. A platform referred to as Neuroglee Join will give clinicians, caregivers and sufferers entry to help and options for reimbursement and protection.

#Neuroglee #million #develop #digital #therapeutics #neurodegenerative #illnesses #PJDM


Catherine Shu